Reich, K., Simpson, E., Langley, R., Warren, R., Costanzo, A. , Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., De Bruin Weller, M. and Blauvelt, A. 2023. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s143. DOI:https://doi.org/10.25251/skin.7.supp.143.